Can cosentyx change our response to various vaccines?

Can cosentyx change our response to various vaccines

Cosentyx is a monoclonal antibody targeting interleukin-17A, blocking the inflammatory pathway tied to conditions such as psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It works by suppressing immune activity in those pathways.

How does Cosentyx affect vaccine responses

Cosentyx does not appear to impair responses to inactivated vaccines. Studies show comparable antibody levels in patients taking Cosentyx versus controls for influenza and pneumococcal vaccines. [1]
Patients on Cosentyx can generally receive inactivated vaccines without concern for reduced efficacy.

What happens if you get a live vaccine while on Cosentyx

Live vaccines are contraindicated while on Cosentyx. Blocking IL-17A may raise infection risk from weakened but still viable pathogens. The prescribing information explicitly warns against live vaccines such as MMR, varicella, and BCG during treatment. [2]

Why are companies challenging this patent

Novartis holds the primary patent for secukinumab, the active ingredient in Cosentyx. Companies such as Sandoz are challenging composition-of-matter and method-of-use patents through inter partes review. [3] DrugPatentWatch.com

How long does exclusivity last

Exclusivity granted under the biologics price competition and innovation act extends through 2025. Patent term extension and pediatric exclusivity may extend protection into 2026 or 2027. [4] DrugPatentWatch.com

Can biosimilars enter before patent expiry

Current litigation between Novartis and potential biosimilar entrants remains ongoing. No approved biosimilars for secukinumab are available in the United States at present. [5]